PropertyValue
?:abstract
  • In response to the COVID-19 pandemic, there has been a rapid growth in research focused on developing vaccines and therapies. In this context, the need for speed is taken for granted, and the scientific process has adapted to accommodate this. On the surface, attempts to speed up the research enterprise appear to be a good thing. It is, however, important to consider what, if anything, might be lost when biomedical innovation is sped up. In this article we use the case of a study recently retracted from the Lancet to illustrate the potential risks and harms associated with speeding up science. We then argue that, with appropriate governance mechanisms in place (and adequately resourced), it should be quite possible to both speed up science and remain attentive to scientific quality and integrity.
?:creator
?:doi
?:doi
  • 10.1007/s11673-020-10013-y
?:journal
  • J_Bioeth_Inq
?:license
  • no-cc
?:pdf_json_files
  • document_parses/pdf_json/dd513f868d510806519057fad560003f39ab0d8d.json
?:pmc_json_files
  • document_parses/pmc_json/PMC7445735.xml.json
?:pmcid
?:pmid
?:pmid
  • 32840838.0
?:publication_isRelatedTo_Disease
?:sha_id
?:source
  • Medline; PMC
?:title
  • Science at Warp Speed: Medical Research, Publication, and Translation During the COVID-19 Pandemic
?:type
?:year
  • 2020-08-25

Metadata

Anon_0  
expand all